Cleavable vs. Non-Cleavable ADC Linkers: Which Antibody–Drug Conjugate Strategy Is Better?

Cleavable linkers are designed to break under specific biological conditions. Some are sensitive to acidic environments, such as those found in endosomes and lysosomes. Others are cleaved by intracellular proteases or reduced by high intracellular concentrations of glutathione. Once the linker is cleaved, the cytotoxic payload is released in a form that can act on its intracellular target.

This release mechanism can be highly advantageous when the payload is membrane-permeable. After being released inside an antigen-positive tumor cell, the payload may diffuse into neighboring tumor cells that express lower levels of the target antigen. This bystander effect can improve activity against tumors with heterogeneous antigen expression.

Non-cleavable linkers operate differently. They are designed to remain stable throughout circulation and intracellular trafficking. After the ADC binds to its target antigen and is internalized, the antibody is degraded in the lysosome. The payload remains attached to a linker-amino acid residue derived from the antibody. This metabolite must retain cytotoxic activity to produce the desired antitumor effect.

Because non-cleavable linkers generally require full internalization and lysosomal degradation, they are especially dependent on target biology. The target antigen must be efficiently internalized, and the resulting payload metabolite must be active within the tumor cell.

From a manufacturing perspective, both cleavable and non-cleavable linker strategies can be incorporated into established ADC conjugation workflows, but they create different development and analytical priorities.

Cleavable linkers require careful optimization of chemical stability. The linker must remain stable during manufacturing, storage, and circulation, but release payload efficiently once the ADC reaches the intended intracellular environment. This balance can be difficult to achieve, particularly for linkers sensitive to pH, enzymes, or reducing conditions that may vary across tissues and patients.

Non-cleavable linkers can offer advantages in systemic stability and product control. Because they are less likely to release payload before internalization, they may reduce off-target toxicity associated with free drug exposure. This stability can simplify some aspects of formulation and handling, although the final ADC still requires rigorous characterization of drug-to-antibody ratio, aggregation, free payload, and conjugation-related impurities.

The payload itself also strongly influences linker selection. Some payloads require release in an unmodified form to be active, making cleavable linkers more attractive. Others retain activity when attached to a linker-derived residue, making them compatible with non-cleavable designs.

Ultimately, linker selection cannot be separated from the full ADC architecture. The antibody, antigen, conjugation site, drug-to-antibody ratio, linker, and payload must be optimized as an integrated system.

Cleavable linkers are typically preferred when:

• tumor antigen expression is heterogeneous

• a bystander effect is desirable

• the payload must be released in a free or near-free form

• intracellular tumor conditions provide a reliable release trigger

• strong potency is needed across mixed tumor cell populations

Non-cleavable linkers are typically preferred when:

• plasma stability and controlled payload release are top priorities

• the target antigen internalizes efficiently

• toxicity from premature payload release is a major concern

• the payload remains active as a linker-associated metabolite

• developers want payload activity largely confined to antigen-positive cells

Cleavable linkers offer flexibility and potency advantages, particularly for tumors with heterogeneous antigen expression. By releasing membrane-permeable payloads inside target cells, they can enable bystander killing that extends activity beyond cells with high antigen expression. This can be valuable in solid tumors, where antigen distribution is often uneven.

Non-cleavable linkers offer a different advantage: control. Their stability in circulation can reduce premature payload release and may support a more predictable safety profile. They are especially attractive when the target antigen internalizes efficiently and when the payload remains active after lysosomal degradation of the antibody.

The best linker strategy is therefore not determined by linker class alone. It depends on the biology of the target, the permeability and potency of the payload, the desired degree of bystander killing, and the safety risks associated with systemic exposure. In modern ADC design, cleavable and non-cleavable linkers are best understood as complementary tools for shaping the therapeutic window.